Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bluejay Diagnostics (BJDX) Capital Expenditures (2022 - 2023)

Bluejay Diagnostics (BJDX) has disclosed Capital Expenditures for 2 consecutive years, with $87894.0 as the latest value for Q4 2023.

  • Quarterly Capital Expenditures rose 109.55% to $87894.0 in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $704166.0 through Dec 2023, up 1610.84% year-over-year, with the annual reading at $173735.0 for FY2025, 43.37% down from the prior year.
  • Capital Expenditures hit $87894.0 in Q4 2023 for Bluejay Diagnostics, up from $74498.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $791464.0 in Q3 2022 to a low of -$919904.0 in Q4 2022.